SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid
Data up to Jan 2025
Total Citations Per Year
Abstract
References (45)
Regulation of the mevalonate pathway
1990 • 5,282 citations
Statin-Associated Myopathy
2003 • 1,447 citations
Organic anion transporting polypeptides of the OATP/ SLC21 family: phylogenetic classification as OATP/ SLCO superfamily, new nomenclature and molecular/functional properties
2004 • 976 citations
Incidence of Hospitalized Rhabdomyolysis in Patients Treated With Lipid-Lowering Drugs
2004 • 881 citations
A Novel Human Hepatic Organic Anion Transporting Polypeptide (OATP2)
1999 • 630 citations
Polymorphisms in OATP-C
2001 • 605 citations
Drug and Bile Acid Transporters in Rosuvastatin Hepatic Uptake: Function, Expression, and Pharmacogenetics
2006 • 585 citations
Identification of a Novel Gene Family Encoding Human Liver-specific Organic Anion Transporter LST-1
1999 • 546 citations
Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: Consequences for pravastatin pharmacokinetics
2003 • 514 citations
Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment
2005 • 459 citations
Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans
2004 • 438 citations
Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase Inhibitors
2002 • 422 citations
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)
2004 • 419 citations
Gemfibrozil and Its Glucuronide Inhibit the Organic Anion Transporting Polypeptide 2 (OATP2/OATP1B1:SLC21A6)-Mediated Hepatic Uptake and CYP2C8-Mediated Metabolism of Cerivastatin: Analysis of the Mechanism of the Clinically Relevant Drug-Drug Interaction between Cerivastatin and Gemfibrozil
2004 • 403 citations
Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole*
1998 • 402 citations
Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells
2005 • 368 citations
Inhibition of Transporter-Mediated Hepatic Uptake as a Mechanism for Drug-Drug Interaction between Cerivastatin and Cyclosporin A
2003 • 344 citations
Glucuronidation of Statins in Animals and Humans: A Novel Mechanism of Statin Lactonization
2002 • 342 citations
Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine
2004 • 320 citations
Genetic Polymorphisms of Human Organic Anion Transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): Allele Frequencies in the Japanese Population and Functional Analysis
2002 • 316 citations
Grapefruit juice—simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors*
1998 • 301 citations
Current overview of statin-induced myopathy
2004 • 295 citations
Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics
2004 • 293 citations
Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations*
1998 • 287 citations
In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s.
1997 • 274 citations
Plasma concentrations of active simvastatin acid are increased by gemfibrozil
2000 • 258 citations
Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug.
1990 • 240 citations
Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes.
2001 • 211 citations
DIFFERENTIAL INTERACTION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE INHIBITORS WITH ABCB1, ABCC2, AND OATP1B1
2004 • 206 citations
Human Hepatobiliary Transport of Organic Anions Analyzed by Quadruple-Transfected Cells
2005 • 200 citations
Lipid-lowering response to statins is affected by CYP3A5 polymorphism
2004 • 196 citations
Clinical Pharmacokinetics and Practical Applications of Simvastatin
1993 • 182 citations
The human hepatic metabolism of simvastatin hydroxy acid is mediated primarily by CYP3A, and not CYP2D6
2003 • 180 citations
Effect of () variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers
2005 • 171 citations
Effect of Genetic Polymorphism of OATP-C (SLCO1B1) on Lipid-Lowering Response to HMG-CoA Reductase Inhibitors
2004 • 144 citations
Plasma Concentration Profiles of Simvastatin 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitory Activity in Kidney Transplant Recipients with and without Ciclosporin
1993 • 138 citations
Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17
2005 • 127 citations
Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver.
1999 • 124 citations
Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population
2006 • 118 citations
Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport
2005 • 96 citations
A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro.
2001 • 86 citations
Microsample Determination of Lovastatin and its Hydroxy Acid Metabolite in Mouse and Rat Plasma by Liquid Chromatography/Ionspray Tandem Mass Spectrometry
1997 • 53 citations
3-Hydroxy-3-methylglutaryl–coenzyme a reductase inhibitors (statins) and genetic variability (single nucleotide polymorphisms) in a hepatic drug uptake transporter: what's it all about?
2004 • 52 citations
Inhibition of rhodamine 123 secretion by cyclosporin A as a model of P-glycoprotein mediated transport in liver.
1994 • 31 citations
OATP-C(OATP01B1)*15 is associated with statin-induced myopathy in hypercholesterolemic patients
2005 • 25 citations